结缔组织病患者胸主动脉腔内修复术的预后:血管质量倡议的启示
本研究基于血管质量倡议数据库,纳入2014至2024年间330例接受TEVAR的结缔组织病患者,评估其围手术期和中期结局。结果显示围手术期死亡率、脊髓缺血和卒中均为2.1%,中期再干预率30.8%,动脉瘤退变率40.2%,夹层进展率20.4%。结论认为TEVAR在结缔组织病患者中围手术期并发症可接受,但主动脉相关并发症和再干预风险高,应谨慎使用。
要点
- 结缔组织病患者TEVAR围手术期死亡、脊髓缺血、卒中各为2.1%。
- 18个月随访再干预率30.8%,动脉瘤退变率40.2%,夹层进展率20.4%。
- 马凡综合征患者中期生存率高于Loeys-Dietz或Ehlers-Danlos综合征患者。
核心结论
- TEVAR在结缔组织病患者中围手术期并发症可接受,但早期和中期主动脉相关并发症及再干预风险高,应谨慎使用并主要限于急诊或精心选择的患者。
研究设计与样本
- 回顾性队列研究,使用血管质量倡议数据库,纳入2014至2024年间因胸主动脉瘤或B型主动脉夹层接受TEVAR的330例结缔组织病患者。
- 排除破裂动脉瘤、创伤或转为开放手术的患者。
- 结缔组织病定义为有马凡综合征、Loeys-Dietz综合征或Ehlers-Danlos综合征的临床或遗传学记录。
- 按主动脉病理(胸主动脉瘤 vs B型主动脉夹层)和结缔组织病病理(马凡综合征 vs Loeys-Dietz/Ehlers-Danlos综合征)分层比较。
- 采用Kaplan-Meier分析评估中期生存、再干预、动脉瘤退变和夹层进展事件率。
主要发现
- 330例患者中位年龄50岁(IQR 35-61),85%(n=281)为马凡综合征,13%(n=42)为Loeys-Dietz综合征,2%(n=7)为Ehlers-Danlos综合征。
- 63%(n=208)因B型主动脉夹层接受TEVAR,37%(n=122)因胸主动脉瘤,8%(n=25)为急诊手术。
- 中位住院时间5天(IQR 3-9),围手术期死亡率、脊髓缺血和卒中各为2.1%(n=7),再干预率10.9%(n=36)。
- B型主动脉夹层患者住院时间更长(6天 vs 5天,P=0.017)且围手术期死亡率更高(3.4% vs 0.0%,P=0.039)。
- 马凡综合征患者围手术期死亡率低于Loeys-Dietz或Ehlers-Danlos综合征患者(1.4% vs 6.1%,P=0.036)。
关键数值与推荐
- 动脉瘤退变定义为主动脉直径较基线增加≥5 mm,夹层进展包括顺行和/或逆行夹层。
临床怎么用
- TEVAR在结缔组织病患者中应谨慎使用,主要保留用于急诊情况或经过仔细选择的患者。
- 术后需密切监测主动脉相关并发症和再干预风险。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Open surgical repair continues to be the standard of care for treating thoracic aortic aneurysms (TAAs) and type B aortic dissection (TBAD) in patients with connective tissue disorders (CTDs). Data on the safety and durability of thoracic endovascular aortic repair (TEVAR) in this patient population remains limited. This study aims to evaluate the perioperative and mid-term outcomes of TEVAR in patients with CTDs. METHODS: Patients with CTD who underwent TEVAR for TAA or TBAD between 2014 and 2024 were identified in the Vascular Quality Initiative. Patients with ruptured aneurysms, trauma, or those converted to open surgery were excluded. CTD were defined as any documented clinical or genetic history of Marfan syndrome, Loeys-Dietz syndrome, or Ehlers-Danlos syndrome. Patients were stratified and compared by aortic pathology (TAA versus TBAD) and CTD pathology (Marfan syndrome versus Loeys-Dietz/Ehlers-Danlos syndrome). Kaplan-Meier analysis was used to evaluate and compare the mid-term event rates of survival, aortic reintervention, aneurysmal degeneration, and dissection propagation. Aneurysmal degeneration was defined as a ≥5 mm increase in aortic diameter from baseline, whereas dissection propagation included antegrade and/or retrograde dissection. RESULTS: 330 patients (median age 50 years [interquartile range [IQR], 35-61]) with CTD underwent TEVAR during the study period, of which 85% (n = 281) had Marfan syndrome, 13% (n = 42) had Loeys-Dietz syndrome, and 2% (n = 7) had Ehlers-Danlos syndrome. TEVAR was performed for TBAD in 63% (n = 208) of patients and TAA in 37% (n = 122), with 8% (n = 25) of procedures performed in an emergent setting. Median hospital stay was 5 days (IQR, 3-9). Perioperative mortality, spinal cord ischemia (SCI), and stroke each occurred in 2.1% (n = 7) of patients, and reintervention was required in 10.9% (n = 36). Patients undergoing TEVAR for TBAD had a longer hospital stay (6 days vs 5 days, P = 0.017) and higher perioperative mortality (3.4% vs 0.0%, P = 0.039) compared with TAA. Marfan syndrome patients had a significantly lower rate of perioperative mortality (1.4% vs 6.1%, P = 0.036) than those with Loeys-Dietz syndrome or Ehlers-Danlos syndrome. At 18-month follow up, overall survival was 88.1% (95% confidence interval [CI], 84.2%-92.0%), with reintervention occurring in 30.8% (95% CI, 23.9%-37.7%), aneurysmal degeneration in 40.2% (95% CI, 29.8%-50.6%), and dissection propagation in 20.4% (95% CI, 10.8%-30.0%). Mid-term outcomes were similar between TBAD and TAA for survival (P = 0.369), reintervention (P = 0.896), aneurysmal degeneration (P = 0.151), and dissection propagation (P = 0.810). Patients with Marfan syndrome had a higher mid-term survival compared to patients with Loeys-Dietz or Ehlers-Danlos syndrome (91.0% vs 71.6%, P = 0.001), with no difference observed in reintervention (P = 0.190), aneurysmal degeneration (P = 0.496), or dissection propagation (P = 0.445). CONCLUSION: TEVAR in patients with CTD is associated with acceptable perioperative morbidity and mortality but carries a substantial risk of early and mid-term aortic-related complications and reintervention. TEVAR should be used cautiously in this population and primarily reserved for emergency situations or carefully selected patients.
引用
- Chamseddine H, Halabi M, Shepard A, et al. Outcomes of Thoracic Endovascular Aortic Repair for Thoracic Aortic Disease in Patients with Connective Tissue Disorders: Insights from the Vascular Quality Initiative. Ann Vasc Surg. 2026. PMID: 42442531. doi:10.1016/j.avsg.2026.06.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。